# ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

> **NCT07157969** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 300 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Camrelizumab
- **DRUG:** Apatinib
- **PROCEDURE:** TACE
- **PROCEDURE:** HAIC
- **PROCEDURE:** DEB-TACE
- **DRUG:** Tislelizumab
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT07157969
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-19
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07157969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07157969, "ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07157969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*